Doramapimod
Alternative Names: BIBR 796; BIRB 796; BIRB 796 BS; BIRB-0796Latest Information Update: 02 Oct 2021
At a glance
- Originator Boehringer Ingelheim
- Class Anti-inflammatories; Antirheumatics; Pyrazoles; Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Crohn's disease; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 03 Dec 2009 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 16 Feb 2005 Preclinical trials in Cancer in USA (unspecified route)
- 22 May 2002 Phase-II clinical trials in Psoriasis (unspecified route)